Qing Yi

Qing Yi, MD, PhD

Ralph O’Connor Centennial Chair, Dr. Mary and Ron Neal Cancer Center
Professor of Oncology, Academic Institute
Full Member, Research Institute
Director, Center for Translational Research in Hematological Malignancies
Associate Director, Cancer Center Basic Research Programs, Dr. Mary and Ron Neal Cancer Center
Houston Methodist
Weill Cornell Medical College


Qing Yi Lab


Biography

Dr. Qing Yi is a trained medical immunologist with over 25 years of experience as a well-funded and published researcher. He is one of the leading investigators in the fields of tumor immunology and immunotherapy in multiple myeloma and other cancers.

Since arriving in the US in 1998, Dr. Yi has been awarded, as the PI, 9 R01s from NCI, 1 project and 1 core grant in the MDACC Myeloma SPORE (P50), 4 R01-type translational grants from the LLS, 4 Senior Researcher Awards from the MMRF, 2 K99/R00 grants (as the mentor), and numerous intramural and industry grants. Dr. Yi and colleagues have published more than 160 peer-reviewed research articles, with 45 being in top-tier journals with an impact factor of greater than 10.

Prior to his current appointment as Associate Director of the Houston Methodist Cancer Center, Dr. Yi had faculty appointments at Lerner Research Institute at the Cleveland Clinic in Ohio, MD Anderson Cancer Center, University of Arkansas for Medical Sciences, and Karolinska Hospital and Institute, Sweden.

Description of Research

For the past two decades, Dr. Yi's laboratory has been working on the following research:

(1) characterizing myeloma- and tumor-specific T cells and their subsets and examining their functions in relationship to myeloma tumor cells using both in vitro and in vivo approaches

(2) identifying novel myeloma-associated antigens and better methods for immunotherapy

(3) investigating the cross-talk between the tumor microenvironment and the immune system in malignancy

(4) clinical trials to evaluate the efficacy of immunizing patients with idiotype or dendritic cell-based vaccines

(5) exploring immunotherapies using novel myeloma antigens such as DKK1 in multiple myeloma. Our recent research focuses on (a) developing novel therapeutic monoclonal antibodies for myeloma and other cancers, (b) identifying T-cell subsets that have potent anti-tumor effects after adoptive transfer, and (c) identifying tumor microenvironment components that induce tumor drug resistance.

A commentary written by Dr. Edgar Schmitt and Dr. Tobias Bopp in J Clin Invest (122:3857-3859) comments that “During the last two decades the laboratory of Qing Yi has significantly contributed to our current understanding of potential immunotherapies in human malignancies by describing the role of DCs – and particular T cells – in multiple myeloma.”

 

Areas Of Expertise

Cancer immunotherapy Hematological malignancies Myeloma Cancer biology
Education & Training

MB MMed, Sun Yat-sen Univ. of Med. Sciences
MD, Jiangxi Medical College, Jiangxi, P.R. China
Postdoctoral Fellowship, Karolinska Institute
PhD, Karolinska Institute
Publications

BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions
Zhang, D, Huang, J, Wang, F, Ding, H, Cui, Y, Yang, Y, Xu, J, Luo, H, Gao, Y, Pan, L, Wu, Y, Gong, Y, Xie, L, Liu, Z, Qu, Y, Zhang, L, Liu, W, Zhang, W, Zhao, S, Yi, Q, Niu, T & Zheng, Y 2021, , Cell death & disease, vol. 12, no. 5, pp. 495. https://doi.org/10.1038/s41419-021-03748-y

CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability
Ma, X, Xiao, L, Liu, L, Ye, L, Su, P, Bi, E, Wang, Q, Yang, M, Qian, J & Yi, Q 2021, , Cell Metabolism, vol. 33, no. 5, pp. 1001-1012.e5. https://doi.org/10.1016/j.cmet.2021.02.015

Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma
Li, R, Zheng, C, Wang, Q, Bi, E, Yang, M, Hou, J, Fu, W, Yi, Q & Qian, J 2021, , Haematologica, vol. 106, no. 3, pp. 838-846. https://doi.org/10.3324/haematol.2019.236836

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma
Li, Z, Liu, H, He, J, Wang, Z, Yin, Z, You, G, Wang, Z, Davis, RE, Lin, P, Bergsagel, PL, Manasanch, EE, Wong, STC, Esnaola, NF, Chang, JC, Orlowski, RZ, Yi, Q & Yang, J 2021, , Cell Metabolism, vol. 33, no. 1, pp. 78-93.e7. https://doi.org/10.1016/j.cmet.2020.12.011

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
Tseng, HC, Xiong, W, Badeti, S, Yang, Y, Ma, M, Liu, T, Ramos, CA, Dotti, G, Fritzky, L, Jiang, JG, Yi, Q, Guarrera, J, Zong, WX, Liu, C & Liu, D 2020, , Nature Communications, vol. 11, no. 1, 4810. https://doi.org/10.1038/s41467-020-18444-2

Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9
Liu, L, Bi, E, Ma, X, Xiong, W, Qian, J, Ye, L, Su, P, Wang, Q, Xiao, L, Yang, M, Lu, Y & Yi, Q 2020, , Nature Communications, vol. 11, no. 1, 5902. https://doi.org/10.1038/s41467-020-19672-2

MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma
Wang, Q, Zhao, D, Xian, M, Wang, Z, Bi, E, Su, P, Qian, J, Ma, X, Yang, M, Liu, L, Zu, Y, Pingali, SR, Chen, K, Cai, Z & Yi, Q 2020, , Blood, vol. 136, no. 22, pp. 2557-2573. https://doi.org/10.1182/blood.2020005795

Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma
Hu, Y, Liu, H, Fang, C, Li, C, Xhyliu, F, Dysert, H, Bodo, J, Habermehl, G, Russell, BE, Li, W, Chappell, M, Jiang, X, Ondrejka, SL, Hsi, ED, Maciejewski, JP, Yi, Q, Anderson, KC, Munshi, NC, Ao, G, Valent, JN, Lin, J & Zhao, J 2020, , Cancer research, vol. 80, no. 10, pp. 2031-2044. https://doi.org/10.1158/0008-5472.CAN-19-1077

Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages
Su, P, Wang, Q, Bi, E, Ma, X, Liu, L, Yang, M, Qian, J & Yi, Q 2020, , Cancer research, vol. 80, no. 7, pp. 1438-1450. https://doi.org/10.1158/0008-5472.CAN-19-2994

Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma
Li, R, Zheng, C, Wang, Q, Bi, E, Yang, M, Hou, J, Fu, W, Yi, Q & Qian, J 2020, , Haematologica. https://doi.org/10.3324/haematol.2019.236836

The many substrates and functions of NEDD4-1
Huang, X, Chen, J, Cao, W, Yang, L, Chen, Q, He, J, Yi, Q, Huang, H, Zhang, E & Cai, Z 2019, , Cell Death and Disease, vol. 10, no. 12, 904. https://doi.org/10.1038/s41419-019-2142-8

CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma
Xu, R, Li, Y, Yan, H, Zhang, E, Huang, X, Chen, Q, Chen, J, Qu, J, Liu, Y, He, J, Yi, Q & Cai, Z 2019, , Cell death & disease, vol. 10, no. 10, pp. 781. https://doi.org/10.1038/s41419-019-2012-4

Cholesterol induces T cell exhaustion
Ma, X & Yi, Q 2019, , Aging, vol. 11, no. 18, pp. 7334-7335. https://doi.org/10.18632/aging.102305

The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma
Huang, X, Gu, H, Zhang, E, Chen, Q, Cao, W, Yan, H, Chen, J, Yang, L, Lv, N, He, J, Yi, Q & Cai, Z 2019, , International Journal of Cancer. https://doi.org/10.1002/ijc.32615

Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease
Liu, H, He, J, Koh, SP, Zhong, Y, Liu, Z, Wang, Z, Zhang, Y, Li, Z, Tam, BT, Lin, P, Xiao, M, Young, KH, Amini, B, Starbuck, MW, Lee, HC, Navone, NM, Davis, RE, Tong, Q, Bergsagel, PL, Hou, J, Yi, Q, Orlowski, RZ, Gagel, RF & Yang, J 2019, , Science translational medicine, vol. 11, no. 494, eaau9087. https://doi.org/10.1126/scitranslmed.aau9087

Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment
Ma, X, Bi, E, Lu, Y, Su, P, Huang, C, Liu, L, Wang, Q, Yang, M, Kalady, MF, Qian, J, Zhang, A, Gupte, AA, Hamilton, DJ, Zheng, C & Yi, Q 2019, , Cell Metabolism, vol. 30, no. 1, pp. 143-156.e5. https://doi.org/10.1016/j.cmet.2019.04.002

Multiple myeloma cell-derived IL-32? increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression
Yan, H, Dong, M, Liu, X, Shen, Q, He, D, Huang, X, Zhang, E, Lin, X, Chen, Q, Guo, X, Chen, J, Zheng, G, Wang, G, He, J, Yi, Q & Cai, Z 2019, , Cancer Letters, vol. 446, pp. 38-48. https://doi.org/10.1016/j.canlet.2019.01.012

TNF-a enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways
Jiang, Y, Chen, J, Bi, E, Zhao, Y, Qin, T, Wang, Y, Wang, A, Gao, S, Yi, Q & Wang, S 2019, , Journal for immunotherapy of cancer, vol. 7, no. 1, 28. https://doi.org/10.1186/s40425-018-0494-8

MicroRNA-31-5p enhances the Warburg effect via targeting FIH
Zhu, B, Cao, X, Zhang, W, Pan, G, Yi, Q, Zhong, W & Yan, D 2019, , FASEB journal : official publication of the Federation of American Societies for Experimental Biology, vol. 33, no. 1, pp. 545-556. https://doi.org/10.1096/fj.201800803R

E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs
Bi, E, Li, R, Bover, LC, Li, H, Su, P, Ma, X, Huang, C, Wang, Q, Liu, L, Yang, M, Lin, Z, Qian, J, Fu, W, Liu, Y-J & Yi, Q 2018, , The Journal of clinical investigation, vol. 128, no. 11, pp. 4821-4831. https://doi.org/10.1172/JCI121421